Data updated: May 26, 2026
VAZALORE (aspirin)
Pain
Approved 2013-01-14
1
Indication
--
Phase 3 Trials
13
Years on Market
Details
- Status
- Over-the-counter
- First Approved
- 2013-01-14
- Patent Cliff
- 2032
- Routes
- ORAL
- Dosage Forms
- CAPSULE
VAZALORE Approval History
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
14 FDA actions from 2013 to 2022
Jan 2014 SUPPL
Mfg
What VAZALORE Treats
1 FDA approvalsOriginally approved for its first indication in 2013 .
- Other (1)
📋
Clinical Trial Registry
246 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07572747 ARCTURUS-GTC-1 | — | Ph 3 | not yet recruiting | Aspirin Versus Clopidogrel in Chronic Coronary Syndrome in Arabian Gulf Countries |
| NCT03907046 ASPIRE | 2000026409 1U01NS106513-01A1 | Ph 3 | recruiting | Anticoagulation in ICH Survivors for Stroke Prevention and Recovery |
| NCT05955365 MATRIX-2 | MATRIX-2 | Ph 4 | recruiting | Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation |
| NCT05625724 APPART | RC31/21/0337 | Ph 3 | recruiting | Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology |
| NCT04770012 | 2020-version 1.0 | Ph 3 | recruiting | AERIAL Trial: Antiplatelet Therapy in Heart Transplantation |
| NCT06710184 FOXY | DAN-FOXY 2024-517229-18-00 | Ph 4 | recruiting | Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction |
| NCT02521285 results posted | NCI-2015-01265 NCI-2015-01265, 2013-0819 | Ph 2 | active not recruiting | Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation |
| NCT02044250 | HOST-EXAM Trial | Ph 4 | completed | Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM) |
| NCT04381936 RECOVERY | NDPHRECOVERY 2020-001113-21, ISRCTN50189673 | Ph 3 | recruiting | Randomised Evaluation of COVID-19 Therapy |
| NCT07540416 TRUST-MISMATCH | MISMATCH-001 | Ph 3 | not yet recruiting | Tenecteplase for Late-Window Stroke Guided by DWI-FLAIR Mismatch |
| NCT04078568 | KD-3-01 | Ph 3 | completed | Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease |
| NCT02965703 results posted | NCI-2016-01642 NCI-2016-01642, N01-CN-2012-00035 | Ph 2 | active not recruiting | Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma |
| NCT05418556 OPTIMIZE-APT | 2022-0568 | Ph 4 | recruiting | Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent |
| NCT03574909 IRELAnD | Ireland-Rct-v1-0218 2018-000770-29 | Ph 3 | completed | IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes |
| NCT06757764 CHANGE | CHANGE | Ph 4 | recruiting | The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis |
| NCT06650488 Clopido-SNAP 2 | 2025-10899 500048 | Ph 4 | recruiting | Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia |
| NCT03796156 ATTACK | 31844 | Ph 3 | terminated | Aspirin to Target Arterial Events in Chronic Kidney Disease |
| NCT06451198 OPTION2 | B2024-187 | Ph 4 | recruiting | IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome |
| NCT04295486 | 20190973 | Ph 2 | recruiting | Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty |
| NCT05633810 COLCOT-T2D | MHICC-2021-001 | Ph 3 | recruiting | COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes |
| NCT04809818 results posted | LT3001-105 | Ph 1 | completed | A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects |
| NCT06655376 | AAAV3358 | Ph 4 | recruiting | Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device |
| NCT07431762 CONCLAVE | 2025-1499 | Ph 4 | not yet recruiting | Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Heart Valve Replacement |
| NCT06676280 ASA-3C | AMCCV 2024-01 | Ph 4 | recruiting | ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography |
| NCT07373756 | 599/2025 | Ph 4 | not yet recruiting | Randomized Controlled Study to Compare Efficacy of Aspirin 75mg and 150mg In the Prevention of Preeclampsia In High Risk Pregnant Women |
| NCT07361679 preGO | 724/23-11-2022 | Ph 4 | recruiting | LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention |
| NCT05310968 STRATEGY | KY2021-089-08 | Ph 4 | completed | Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction |
| NCT04912505 ASPIRE | RC31/19/0509 | Ph 2 | completed | ASPirin in Immune thRombocytopenia Patients With Cardiovascular disEase |
| NCT01729468 PERASTUN | PHRN08-FP/PERASTUN 2011-003536-30, 2012-R8 | Ph 4 | completed | Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers |
| NCT06548971 TREND-IVT | TREND-IVT | Ph 3 | recruiting | Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT) |
| NCT03079999 | 17-030 W81XWH-17-1-0644 | Ph 2 | active not recruiting | Study of Aspirin in Patients With Vestibular Schwannoma |
| NCT04188119 IMpALA | CFT / sp123 2018-004121-80, 017NovCC107 | Ph 2 | withdrawn | A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer |
| NCT03378934 APLABE-PCI | 2016-I2M-1-011 JS-1375 | Ph 4 | recruiting | Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention |
| NCT05411718 | 2022-0117 NCI-2022-04794, 1R01CA257375-01 | Ph 2 | recruiting | A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome |
| NCT07180472 | 2025CYFYIRB-BA-113 | Ph 4 | not yet recruiting | Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol |
| NCT03869268 WILLOW TREE results posted | STH20370 | Ph 4 | completed | The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin |
| NCT06638151 CoPrime | Pro00140876 | Ph 2 | recruiting | Clopidogrel Plus Aspirin in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPrime) |
| NCT07153744 MUST Ⅱ | HMPE202501 | Ph 4 | not yet recruiting | Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction |
| NCT06090890 | 2023-GSP-GG-32 | Ph 4 | recruiting | Anti-inflammatory Therapy for Recurrent In-stent Restenosis |
| NCT03805932 results posted | 190042 19-C-0042 | Ph 1 | active not recruiting | Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia |
| NCT06444178 | R9933-HV-2424 | Ph 1 | completed | Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants |
| NCT02467582 results posted | SAKK 41/13 - Aspirin SNCTP000001339, 2015-001482-57 | Ph 3 | terminated | Adjuvant Aspirin Treatment for Colon Cancer Patients |
| NCT05962034 | 21851 | Ph 4 | recruiting | Thromboxane Function in Women With Endometriosis |
| NCT03192215 ARCADIA results posted | AAAR4607 1U01NS095869-01A1 | Ph 3 | terminated | AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke |
| NCT06518317 SOLOTAVI | 2023-508208-40-00 | Ph 3 | recruiting | Short Versus Long Antiplatelet Therapy After TAVI |
| NCT04824911 SATBRAD | 202001386A3 | Ph 2 | completed | Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease |
| NCT04645550 | YZUC-005 | Ph 4 | completed | Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT） |
| NCT05347069 ASA-IN | Y0126 | Ph 4 | recruiting | Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization |
| NCT06494878 | REB24-0317 | Ph 3 | not yet recruiting | The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity |
| NCT03543683 | COAST 1 | Ph 2 | completed | Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC |
Showing 50 of 246 trials
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
VAZALORE FDA Label Details
View full patent landscape →
4 OB patents · 1 families ·
38 international docs across 10 countries
VAZALORE Patents & Exclusivity
Latest Patent: Sep 2032
Patents (4 active)
US9226892
Expires Sep 29, 2032
US10786444
Expires Sep 29, 2032
US10646431
Expires Sep 29, 2032
US9216150
Expires Sep 29, 2032
Source: FDA Orange Book
Pro Intelligence Preview
Deep insights for VAZALORE
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2032
- • 16 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • Competitor tracking
- • Same target/indication analysis
Unlock Full Intelligence
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.